What Charles River Laboratories International (CRL)'s Accelerated, NGS-Enabled Cell Banking Platform Means For Shareholders

Charles River Laboratories International has introduced rapid cell banking programs that shorten cell bank production timelines by about 40% versus the 20‑week industry standard, integrating rapid microbiological methods and CGMP-compliant Next-Generation Sequencing (NGS) to support faster, higher-quality biologic and advanced therapy development. An interesting aspect of this launch is its alignment with Charles River’s Alternative Methods Advancement Project, which aims to cut reliance on...